Clinical efficacy and urodynamic predictors of successful treatment outcomes following urethral sphincter botulinum toxin A injection in women with non-spinal cord neurogenic voiding dysfunction.
Abstract
[PURPOSE] Neurogenic voiding dysfunction caused by neurological diseases is frequently encountered in clinical practice. This study aimed to evaluate the clinical efficacy and identify urodynamic predictors of a successful outcome following urethral sphincter botulinum toxin A (BoNT-A) injection in women with this condition.
[METHODS] This is a retrospective cohort study. Women diagnosed with non-spinal cord neurogenic voiding dysfunction who presented with difficulty voiding and significant post-void residual (PVR) urine volume received 100 units of BoNT-A via urethral sphincter injection. The primary outcome was assessed 3 months posttreatment. Treatment success was defined as improved voiding function with voiding efficiency (VE) > 67% and elimination of catheterization. Patients not meeting these criteria were classified as treatment failures. Baseline videourodynamic parameters were analyzed to identify differences between successful and unsuccessful treatment groups. Multivariate logistic regression was employed to determine independent predictors of treatment success.
[RESULTS] A total of 158 women were enrolled, including 35 with cerebrovascular disease, 22 with Parkinson's disease, 10 with dementia, and 91 with peripheral nervous system disorders. Among them, only 28.5% achieved a successful outcome, while 40.5% showed partial improvement but continued to experience high PVR and required catheterization. Women in the success group exhibited significantly higher baseline voiding pressures, maximum flow rates, and VE, along with lower PVR volumes, compared with those in the failure group. Urethral sphincter discoordination was associated with higher success rates, whereas detrusor underactivity, tight bladder neck, and poor external sphincter relaxation were linked to poorer outcomes.
[CONCLUSION] Higher baseline voiding pressure and lower PVR were predictive of successful response to urethral sphincter BoNT-A injection in women with non-spinal cord neurogenic voiding dysfunction. The result highlights that a woman with true urethral sphincter dysfunction could benefit from urethral BoNT-A injection. Proper patient selection based on urodynamic parameters may optimize therapeutic outcomes.
[METHODS] This is a retrospective cohort study. Women diagnosed with non-spinal cord neurogenic voiding dysfunction who presented with difficulty voiding and significant post-void residual (PVR) urine volume received 100 units of BoNT-A via urethral sphincter injection. The primary outcome was assessed 3 months posttreatment. Treatment success was defined as improved voiding function with voiding efficiency (VE) > 67% and elimination of catheterization. Patients not meeting these criteria were classified as treatment failures. Baseline videourodynamic parameters were analyzed to identify differences between successful and unsuccessful treatment groups. Multivariate logistic regression was employed to determine independent predictors of treatment success.
[RESULTS] A total of 158 women were enrolled, including 35 with cerebrovascular disease, 22 with Parkinson's disease, 10 with dementia, and 91 with peripheral nervous system disorders. Among them, only 28.5% achieved a successful outcome, while 40.5% showed partial improvement but continued to experience high PVR and required catheterization. Women in the success group exhibited significantly higher baseline voiding pressures, maximum flow rates, and VE, along with lower PVR volumes, compared with those in the failure group. Urethral sphincter discoordination was associated with higher success rates, whereas detrusor underactivity, tight bladder neck, and poor external sphincter relaxation were linked to poorer outcomes.
[CONCLUSION] Higher baseline voiding pressure and lower PVR were predictive of successful response to urethral sphincter BoNT-A injection in women with non-spinal cord neurogenic voiding dysfunction. The result highlights that a woman with true urethral sphincter dysfunction could benefit from urethral BoNT-A injection. Proper patient selection based on urodynamic parameters may optimize therapeutic outcomes.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 해부 | cord
|
scispacy | 1 | ||
| 해부 | detrusor
|
scispacy | 1 | ||
| 해부 | urethral BoNT-A
|
scispacy | 1 | ||
| 합병증 | urethral sphincter
|
scispacy | 1 | ||
| 합병증 | peripheral nervous system
|
scispacy | 1 | ||
| 합병증 | bladder neck
|
scispacy | 1 | ||
| 합병증 | urethral sphincter BoNT-A
|
scispacy | 1 | ||
| 약물 | [RESULTS] A
|
scispacy | 1 | ||
| 질환 | cord neurogenic voiding dysfunction
|
scispacy | 1 | ||
| 질환 | Neurogenic voiding dysfunction
|
scispacy | 1 | ||
| 질환 | neurological diseases
|
C0027765
nervous system disorder
|
scispacy | 1 | |
| 질환 | cerebrovascular disease
|
C0007820
Cerebrovascular Disorders
|
scispacy | 1 | |
| 질환 | Parkinson's disease
|
C0030567
Parkinson Disease
|
scispacy | 1 | |
| 질환 | dementia
|
C0011265
Presenile dementia
|
scispacy | 1 | |
| 질환 | peripheral nervous system disorders
|
C4721453
Peripheral Nervous System Diseases
|
scispacy | 1 | |
| 질환 | Urethral sphincter discoordination
|
scispacy | 1 | ||
| 질환 | poor external sphincter relaxation
|
scispacy | 1 | ||
| 질환 | urethral sphincter dysfunction
|
scispacy | 1 | ||
| 기타 | women
|
scispacy | 1 | ||
| 기타 | BoNT-A
→ botulinum toxin A
|
scispacy | 1 | ||
| 기타 | Patients
|
scispacy | 1 | ||
| 기타 | cerebrovascular
|
scispacy | 1 | ||
| 기타 | patient
|
scispacy | 1 |
MeSH Terms
Humans; Female; Botulinum Toxins, Type A; Retrospective Studies; Urodynamics; Middle Aged; Treatment Outcome; Urethra; Aged; Adult; Neuromuscular Agents; Urinary Bladder, Neurogenic; Urination Disorders; Injections
📑 인용 관계
이 논문이 참조한 문헌 37
- The effect of botulinum toxin A in children with non-neurogenic therapy-refractory dysfunctional voi…
- Lower urinary tract dysfunction in the central nervous system neurogenic bladder and the real-life t…
- Predictive Factors for the Successful Outcome of Urethral Sphincter Injections of Botulinum Toxin A …
- Long-term Outcomes of Periurethral Sphincter Botulinum Toxin in Female Chronic Urinary Retention.
- An Alternative Approach for Treating Female Underactive Bladders with Chronic Urine Retention: A Pil…
- Role of Urological Botulinum Toxin-A Injection for Overactive Bladder and Voiding Dysfunction in Pat…
- Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter an…
- Botulinum toxin A injection to the external urethral sphincter for voiding dysfunction in females: A…
- Obstructive patterns in videourodynamic studies predict responses of female dysfunctional voiding tr…
- Efficacy and safety of botulinum toxin a injection into urethral sphincter for underactive bladder.
- Urethral Sphincter Injection of Botulinum Toxin A: A Review of Its Application and Outcomes.
- Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity an…
외부 PMID 25건 (DB 미수집)
- PMID 11257648 ↗
- PMID 12559262 ↗
- PMID 12684605 ↗
- PMID 12875934 ↗
- PMID 14532805 ↗
- PMID 15126771 ↗
- PMID 15578628 ↗
- PMID 16286113 ↗
- PMID 19013594 ↗
- PMID 20001446 ↗
- PMID 22748864 ↗
- PMID 23321659 ↗
- PMID 24323131 ↗
- PMID 26067125 ↗
- PMID 26435296 ↗
- PMID 27037830 ↗
- PMID 29149505 ↗
- PMID 29260540 ↗
- PMID 29279880 ↗
- PMID 30083849 ↗
- PMID 30139634 ↗
- PMID 30308261 ↗
- PMID 37739836 ↗
- PMID 38935322 ↗
- PMID 8583552 ↗
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.